Capabilities by Region: Asia
Greenhill has offices in Hong Kong, Singapore and Tokyo and has considerable advisory experience in Asia. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a network of corporate relationships throughout Asia.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Programmed Maintenance Services Limited
Advised PERSOL HOLDINGS, one of Japan’s largest HR service companies, on its acquisition of ASX-listed Programmed Maintenance Services, a leading Australian and New Zealand based provider of staffing and maintenance services
Inenco Group Pty Ltd
Advised Inenco Group Pty Ltd, one of Australasia’s leading industrial distributors, on the partial sale to Genuine Parts Company, a global distributor of automotive and industrial products
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).